Indoor Air Filtration and Young Adults Health Study

Cardiopulmonary Health Effects of Indoor Air Purification and Other Indoor Environmental Conditions Among Young Healthy Adults in Beijing, China

This study aims to explore the cardiopulmonary health effects of indoor air purification and other indoor environmental conditions among young healthy college students in Beijing, China.

Study Overview

• Status: Completed
• Conditions: Cardiopulmonary Diseases
• Intervention / Treatment: Other: Air purifier

Detailed Description

The present randomized, double-blind crossover study was conducted to investigate the cardiopulmonary health effects of air purification among 81 young healthy college students in Beijing, China. Real or sham purification was performed in the dormitories for 4 days, following a 15-day wash-out period in the intervals. During the study periods, the investigators collected indoor exposure levels of size-fractionated particulate matter (PM), black carbon (BC), noise, ozone, nitrogen dioxide, carbon dioxide, volatile organic compounds, temperature, relative humidity, illumination, and microorganism. Biological specimens (i.e., morning urine, fasting venous blood, exhaled breath condensate, and nasal mucus) were also collected and examined. Some important individual factors including demographical information (age, sex, height, weight, etc.), physical activity, sleep condition, mood and cognition, and food intake were also gathered using questionaire or anthropometric measurements, in order to control for the potential confounding effects. For further data analyses, air pollutants, noise, and other exposures would be controlled as confounders when addressing the health effects associated with air purification, and would also be used to explore their effects on cardiopulmonary health. The interaction effects of air pollutants, noise, and other exposures on cardiopulmonary health would also be explored.

• Study Type: Interventional
• Enrollment (Actual): 81
• Phase: Not Applicable

Contacts and Locations

Study Locations

• China
  • Beijing, China, 100191
    • Peking University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 28 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Living in Beijing for more than one consecutive years;
• College students between 18-28 years;

Exclusion Criteria:

• Current or past smokers;
• Body mass index (BMI) over 28.0 kg/m2.
• Alcohol addict;
• Having thoracic surgery history;
• History of diagnosed chronic disease;
• Hepatitis B / hepatitis C virus patient / carrier;
• Unwilling or unable to provide informed consent or cooperate with all research related procedures.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Real purification; Air purifier turned on.	Other: Air purifier; Real purification and sham purification would be conducted in the dormintory rooms (about 25 in total) of the study subjects for 4 days, following a randomized crossover design, which means a real air purifier and a sham purifier would be placed in the same dormintory room with a wash-out interval (15 days).
Sham Comparator: Sham purification; Air purifier turned off.	Other: Air purifier; Real purification and sham purification would be conducted in the dormintory rooms (about 25 in total) of the study subjects for 4 days, following a randomized crossover design, which means a real air purifier and a sham purifier would be placed in the same dormintory room with a wash-out interval (15 days).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes in heart rate variability	Including the standard deviation of all normal-to-normal R-R intervals (SDNN) in millisecond, standard deviation of sequential five-minute R-R interval means (SDANN) in millisecond, root-mean-square difference of successive normal R-R intervals (rMSSD) in millisecond, low frequency (LF) in squared millisecond, and high frequency (HF) in squared millisecond.	Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
Changes in blood pressure	Including the systolic blood pressure (SBP) in mmHg, diastolic blood pressure (DBP) in mmHg, and pulse pressure (PP) in mmHg.	Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
Changes in pulmonary function	Including forced expiratory volume in 1 s (FEV1) in liter, forced vital capacity (FVC) in liter, forced expiratory volume in 1 s (FEV1) / forced vital capacity (FVC) ratio, and peak expiratory flow (PEF) in liter per second.	Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes in levels of airway inflammation	Respiratory inflammation Fractional exhaled nitric oxide (FeNO) test would be conducted.	Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
Changes in levels of C-reactive protein (CRP)	Examining the C-reactive protein (CRP) in blood sample to characterize the levels of inflammation.	Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
Changes in levels of 8-hydroxydeoxyguanosine (8-OHdG)	Examining the 8-hydroxydeoxyguanosine (8-OHdG) in urine sample to characterize the levels of oxidative stress.	Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
Changes in levels of sleep-related parameters	Including time in bed in minute, total sleep time and sleep stage time in minute. The time in bed and total sleep time would be calculated to sleep efficiency in percentage.	Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
Changes in levels of sleep-breathing parameters	Including blood oxygen saturation in percentage and heart rate in bpm.	Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
Changes in levels of cognitive function	Including short-term memory and delayed memory in unit measured by the standard Stroop Test, as well as executive function in unit measured by the Harmonized Cognitive Assessment Protocol.	Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
Changes in levels of cognitive function-related biomarkers	Including serum brain derived nerve factor (BDNF) in ng/mL, S100B protein in ng/mL, and neuron-specific-enolase (NSE) in ng/mL.	Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
Changes in levels of blood cell parameters	Including white blood cells in unit, red blood cells in unit, and platelets in unit measured by blood routine examination.	Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
Changes in levels of systematic inflammation and oxidative stress indicators	Including interleukin-6 (IL-6) in unit, IL-8 in unit, IL-10 in unit, IL-13 in unit, IL-5 in unit, IL-1β in unit, IL-17A in unit, IL-12p70 in unit, tumor necrosis factor-α (TNF-α) in unit, interferon-γ (IFN-γ) in unit, monocyte chemoattratctant protein-1 (MCP-1) in unit, angiotensin II (Ang-II) in unit, superoxide dismutase (SOD) in unit, glutathione (GSH) in unit, nitric oxide levels (NOX) in unit.	Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
Changes in levels of glucose metabolites in serum	Serum samples were collected for targetted glucose metabolomics analysis using the gas chromatography and mass spectrometry (GC-MS).	Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
Changes in levels of neurotransmitter metabolites in serum	Serum samples were collected for targetted neurotransmitter metabolomics analysis using the gas chromatography and mass spectrometry (GC-MS).	Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
Changes in levels of microbiomics in nasal mucus	Nasal mucus samples were collected for microbiomics analysis to examine the microbial community abundance (α-diversity).	Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
Changes in levels of microbiomics in EBC	EBC samples were collected for microbiomics analysis to examine the microbial community abundance (α-diversity).	Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)
Changes in levels of pituitary-related hormones	Including serum levels of cortisol, adreno-cortico-tropic-hormone (ACTH), and thyroid stimulating hormone (TSH).	Baseline and after the completion of intervention period (a 4-day real purifier intervention or a 4-day sham purifier intervention)

Collaborators and Investigators

• Sponsor: Peking University

Study record dates

Study Major Dates

• Study Start (Actual): December 29, 2021
• Primary Completion (Actual): April 30, 2022
• Study Completion (Actual): April 30, 2022

Study Registration Dates

• First Submitted: November 30, 2021
• First Submitted That Met QC Criteria: December 13, 2021
• First Posted (Actual): December 29, 2021

Study Record Updates

• Last Update Posted (Actual): October 13, 2022
• Last Update Submitted That Met QC Criteria: October 10, 2022
• Last Verified: October 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Pulmonary Heart Disease
• Other Study ID Numbers: IRB00001052-21109

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No